FIELD: immunobiotechnology.
SUBSTANCE: invention relates to soluble CTLA4, which represents mutant variant of wild type CTLA4 and conserves binding ability to CD80 and/or CD86. Molecules of soluble CTLA4 have the first amino acid sequence containing extracellular CTLA4 region, which includes some mutant amino acid residues in S25-R33 region and M97-G107 region. According the present invention mutant molecules also may include second amino acid sequence, enhancing solubility of mutant molecule. Nucleic acid (NA) molecules encoding said CTLA4 and including NA-vectors also are described. Invention also relates to method for production of mutant CTLA4 and uses thereof in controlling of interaction between T-cell and CD80 and/or CD86-positive cell; suppression of graft-versus-host reaction; and treatment of immune system diseases. Soluble mutant CTLA4 according to present invention binds to CD80 and/or CD86 antigen with higher avidity than wild type CTLA4 or non-mutant CTLA41g.
EFFECT: new preparation for treatment of immune system diseases.
65 cl, 19 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF RHEUMATIC DISEASES BY USING SOLUBLE CTLA4 | 2001 |
|
RU2287340C2 |
| SOLUBLE MUTANT CTLA4 MOLECULES | 1998 |
|
RU2235555C2 |
| IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS | 2008 |
|
RU2506275C2 |
| ISOLATED NUCLEIC ACID ENCODING FELINE LIGAND CD86, DIAGNOSTIC OLIGONUCLEOTIDE, CLONING VECTOR, VACCINE, METHODS FOR INDUCTION OR SUPPRESSION OF IMMUNITY IN CAT | 1999 |
|
RU2263145C2 |
| THERAPEUTIC USE OF INHIBITORS OF T-CELL ACTIVATION OR STIMULATION | 2016 |
|
RU2779308C2 |
| NUCLEIC ACIDS, CODING RECEPTOR CTLA-4 OF CAT, VECTORS, HOST CELLS, VACCINES, OLIGONUCLEOTIDES, POLYPEPTIDES CTLA-4 OF CAT AND METHODS FOR INDUCTION AND SUPPRESSION OF IMMUNE RESPONSE IN CAT | 1999 |
|
RU2377302C2 |
| CTLA-4 VARIANTS | 2013 |
|
RU2671465C2 |
| MUTANTS OF ACTIVATION INDUCED CYTIDINE DEAMINASE (AID) AND METHODS OF APPLYING THEREOF | 2010 |
|
RU2537264C2 |
| HUMANIZED MONOCLONAL ANTIBODY RAISED AGAINST AILIM, CO-STIMULATING MOLECULE FOR SIGNAL TRANSFER AND ITS PHARMACEUTICAL APPLYING | 2001 |
|
RU2262511C2 |
| PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE TREATMENT | 2000 |
|
RU2203682C2 |
